Tenax Therapeutics Inc (TENX) Stock Analysis
Verdict: AVOID
Phase 3 trial failure invalidates core pipeline upside despite $97.6M cash runway and aggressive insider accumulation.
Investment score: 38/100
Analysis as of
Is Tenax Therapeutics Inc stock worth reviewing? AI model thesis
The AI model classifies TENX as AVOID due to the Phase 3 trial failure of primary drug candidate TNX-103, which erased 84% of equity value in August 2026. Although $117.98M in balance sheet cash and aggressive insider buying offer a speculative floor around $1.80, the core commercial growth thesis is fundamentally impaired.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 50/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 90/100 (weight 10%)
- Analyst Consensus: 30/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Tenax Therapeutics Inc opportunities and risks
What speaks for TENX
- Subgroup Efficacy in Baseline 6MWD < 333m
What speaks against TENX
- Phase 3 LEVEL Trial Primary Endpoint Failure
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| TENX | n/a | 0.0x | 1.0x | 0.0% | 0.0% | -87.2% |
| PTHS | n/a | 1.7x | n/a | 54.7% | -165.2% | -59.5% |
| OSTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -25.1% |
| GANX | n/a | 0.0x | n/a | 0.0% | 0.0% | -26.1% |
| MAIA | n/a | 0.0x | n/a | 0.0% | 0.0% | -31.5% |
| HRTX | n/a | 0.5x | n/a | 70.1% | -22.5% | -17.8% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -26.1% |
Frequently asked questions about Tenax Therapeutics Inc (TENX)
Is TENX stock a good investment?
The cached TradeMates AI model rates Tenax Therapeutics Inc as AVOID with an investment score of 38/100. The AI model classifies TENX as AVOID due to the Phase 3 trial failure of primary drug candidate TNX-103, which erased 84% of equity value in August 2026. Although $117.98M in balance sheet cash and aggressive insider buying offer a speculative floor around $1.80, the core commercial growth thesis is fundamentally impaired. This is algorithmic model output, not personal investment advice.
Is TENX stock a buy?
The TradeMates model verdict for TENX is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.